Bayesian Networks Decision analysis

Ullrika Sahlin, Centre of Environmental and Climate Research

Lund University, Sweden

Ullrika.Sahlin@cec.lu.se

http://www.cec.lu.se/ullrika-sahlin




Recipe of a decision

- Agents decision makers
- Their values
- Decision alternatives
- An idea of what is a good decision
- Uncertainties in the outcomes of these alternatives


 BN -> Uncertainty quantified by beliefs conditional on available knowledge




Influence diagram




Breast cancer screening






Breast cancer screening — setting impact on values



Advantage	Disadvantage
Death due to breast cancer avoided	Over-diagnoses (cancers detected and treated that would not have caused any harm if left alone)
	Cancer undetected
	False-positive diagnoses requiring further investigation + risk for problems with the biopsy

PSA cancer screening — setting impact on values



Advantage	Disadvantage
Death due to breast cancer avoided + risk for permanent damage	Over-diagnoses (cancers detected and treated that would not have caused any harm if left alone) + risk for permanent damage
	Cancer undetected
	False-positive diagnoses requiring further investigation

PSA cancer screening

Figure 2. Relative risk of prostate cancer death for men screened with PSA versus control participants, by country.

Country	Scree	ned	Con	trol	Risk Ratio		Risk Ratio	
	Deaths	Total	Deaths	Total	(95% CI)		(95% CI)	
LCO trial								
United States	158	38 340	145	38 345	1.09 (0.87–1.36)		-	
RSPC trial								
Sweden	39	5901	70	5951	0.56 (0.38-0.83)		— -	
Belgium	22	4307	25	4255	0.86 (0.48–1.52)			
Netherlands	69	17 443	97	17 390	0.71 (0.52–0.96)			
Italy	19	7266	22	7251	0.86 (0.46–1.58)			
Finland	139	31 970	237	48 409	0.89 (0.72–1.09)		 ■	
Spain	2	1056	1	1141	2.15 (0.20–23.77)	←	-	
Switzerland	9	4948	10	4955	0.89 (0.36–2.20)		-	
						0.2	0.5 1.0 2.0	5
							Favors Screening Favors Contro	

ERSPC = European Randomized Study of Screening for Prostate Cancer; PLCO = Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial; PSA = prostate-specific antigen.

www.annals.org 17 July 2012 Annals of Internal Medicine Volume 157 • Number 2 125

Multi Criteria Decision Analysis

- 1. Define problem & generate alternatives
- 2. Identify criteria to compare alternatives
- 3. Gather value judgments on relative importance of the criteria
- 4. Screen/eliminate clearly inferior alternatives
- 5. Determine performance of alternatives for criteria
- 6. Rand/Select final alternative(s)




Crayfish revisited – Multi Criteria Decision

Analysis

Add poison

attribute




2

Management alternative	Cost	Neg Impact	Acceptance
Do nothing	0	0	0
Mechanical removal	10	2	10

10

5













Crayfish revisited – MCDA




Crayfish again – Adaptive management





Crayfish (oh not again) – Spatial assessment



List

- Set target and derive states that increase the chances of reaching that target in the future
- Value of information analysis (requires utility nodes)
- Sensitivity analysis
- Scenario analysis

Confusion matrix

	Predicted condition		
True condition	Cancer	Not cancer	
Cancer	TP	FN type II error	
Not cancer	FP type I error	TN	

Weighthing of criteria

